Adaptive Biotechnologies (ADPT) shares outstanding
Adaptive Biotechnologies (ADPT) had 151.72M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 3.1% higher than the 147.10M of fiscal 2024. Figures as of 18 Nov 2026, 12:10 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Shares outstanding, fiscal 2025
- 151.72M
- Change on fiscal 2024
- +3.1%
- Growth, 5 years
- +2.9% a year
- Highest on record
- 151.72Mfiscal 2025
- Lowest on record
- 131.22Mfiscal 2020
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Adaptive Biotechnologies shares outstanding, in more detail
The market data feed counts 161.88M shares outstanding today.
Over the five fiscal years to 2025 the diluted share count grew at a compound 2.9% a year. Across the 6 fiscal years on record (2020–2025), the highest was 151.72M in fiscal 2025 and the lowest 131.22M in fiscal 2020.
Shares outstanding by fiscal year
Adaptive Biotechnologies shares outstanding, year by year
| Fiscal year | Shares outstanding | Change | Year ended |
|---|---|---|---|
| 2025 | 151.72M | 3.1% up | |
| 2024 | 147.10M | 1.9% up | |
| 2023 | 144.38M | 1.3% up | |
| 2022 | 142.52M | 1.5% up | |
| 2021 | 140.35M | 7.0% up | |
| 2020 | 131.22M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.
How to read it
A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.
Shares outstanding at health care companies of similar size
| Company | Shares outstanding | Fiscal year |
|---|---|---|
| Dianthus Therapeutics DNTH | 38.62M | 2025 |
| MiniMed Group MMED | 256.60M | 2026 |
| Adaptive Biotechnologies ADPT | 151.72M | 2025 |
| Heartflow HTFL | 36.85M | 2025 |
| CRISPR Therapeutics CRSP | 89.93M | 2025 |
| Travere Therapeutics TVTX | 89.21M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Adaptive Biotechnologies, figure by figure
- Adaptive Biotechnologies market cap
- Adaptive Biotechnologies revenue
- Adaptive Biotechnologies earnings
- Adaptive Biotechnologies earnings per share (EPS)
- Adaptive Biotechnologies P/E ratio
- Adaptive Biotechnologies P/S ratio
- Adaptive Biotechnologies P/B ratio
- Adaptive Biotechnologies free cash flow
- Adaptive Biotechnologies operating margin
- Adaptive Biotechnologies dividend
- Adaptive Biotechnologies total debt
- Adaptive Biotechnologies cash on hand
- Adaptive Biotechnologies total assets
- Adaptive Biotechnologies return on equity (ROE)
- Adaptive Biotechnologies return on invested capital (ROIC)
Adaptive Biotechnologies (ADPT) overview: price, valuation and scorecardAll health care companies by market value
Adaptive Biotechnologies shares outstanding: questions and answers
How many shares does Adaptive Biotechnologies have?
Adaptive Biotechnologies (ADPT) had 151.72M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 3.1% higher than the 147.10M of fiscal 2024. The market data feed counts 161.88M shares outstanding today.
What is the growth rate of Adaptive Biotechnologies's diluted share count?
Over the five fiscal years to 2025 the diluted share count grew at a compound 2.9% a year.
What are the highest and lowest diluted share count figures on record for Adaptive Biotechnologies?
Across the 6 fiscal years on record (2020–2025), the highest was 151.72M in fiscal 2025 and the lowest 131.22M in fiscal 2020.
How is Adaptive Biotechnologies's diluted share count calculated?
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For Adaptive Biotechnologies it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: shares outstanding
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Adaptive Biotechnologies (ADPT) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/ADPT/shares-outstanding
Underlying data: the company's filings with the SEC and Yahoo Finance.